Analyst Activity – Wedbush Reiterates Outperform on Clearside Biomedical (NASDAQ:CLSD)

13

Analyst Ratings For Clearside Biomedical (NASDAQ:CLSD)

Today, Wedbush reiterated its Outperform rating on Clearside Biomedical (NASDAQ:CLSD) with a price target of $27.00.

There are 5 buy ratings on the stock.

The current consensus rating on Clearside Biomedical (NASDAQ:CLSD) is Buy (Score: 3.00) with a consensus target price of $21.75 per share, a potential 190.39% upside.

Some recent analyst ratings include

  • 4/20/2017-Wedbush Reiterated Rating of Outperform.
  • 3/14/2017-Cowen and Company Reiterated Rating of Buy.
  • 2/24/2017-JPMorgan Chase & Co. initiated coverage with a Overweight rating.

Dividend information for Clearside Biomedical (NASDAQ:CLSD)

.

  • On 4/19/2017 Clay Thorp, Director, sold 68,485 with an average share price of $7.46 per share and the total transaction amounting to $510,898.10. View SEC Filing
  • On 4/18/2017 Clay Thorp, Director, sold 44,455 with an average share price of $7.48 per share and the total transaction amounting to $332,523.40. View SEC Filing
  • On 4/17/2017 Clay Thorp, Director, sold 22,000 with an average share price of $7.43 per share and the total transaction amounting to $163,460.00. View SEC Filing
  • On 4/4/2017 Daniel H White, Insider, sold 8,000 with an average share price of $7.55 per share and the total transaction amounting to $60,400.00. View SEC Filing
  • On 4/3/2017 Daniel H White, CEO, sold 3,600 with an average share price of $7.56 per share and the total transaction amounting to $27,216.00. View SEC Filing
  • On 3/20/2017 Christy L Shaffer, Director, bought 2,200 with an average share price of $6.90 per share and the total transaction amounting to $15,180.00. View SEC Filing
  • On 3/16/2017 Clay Thorp, Director, sold 68,485 with an average share price of $6.56 per share and the total transaction amounting to $449,261.60. View SEC Filing

About Clearside Biomedical (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Recent Trading Activity for Clearside Biomedical (NASDAQ:CLSD)
Shares of Clearside Biomedical closed the previous trading session at 7.49 up +0.06 0.81% with 155,638 shares trading hands.